Diabetes and Endocrinology

Two metformin products recalled, more on the way

June 02, 2020

Immediately after the FDA said it found elevated levels of the carcinogenic ingredient N-nitrosodimethylamine (NDMA) in certain extended release (ER) metformin products, the first 2 major recalls are underway.

Pharma exec: New type 2 diabetes treatment competitively priced

September 24, 2019

How the first oral GLP-1 oral treatment for type 2 diabetes is unique and how it will be priced compared to other GLP-1 medications.

FDA clears first ready-to-use insulin for IV infusion

July 22, 2019

FDA approved the first and only ready-to-use insulin for IV infusion in hospitals and acute care settings.

FDA fast tracks blockbuster diabetes drug for heart failure

July 08, 2019

FDA granted Fast Track designation to a popular diabetes drug to reduce the risk of cardiovascular death and hospitalization for heart failure in people with chronic heart failure.

Lack of insulin competition high priority for FDA

April 02, 2019

FDA fast-tracks biosimiliar insulin products to elevate competition.

FDA clears novel diabetes, tropical disease therapies

February 19, 2019

FDA approved first interoperable insulin pump, as well as the only FDA-approved drug for patients with a neglected tropical disease.

Overtreating glucose levels can take a toll on diabetes patients

July 29, 2016

Mayo Clinic researchers found that beyond overtesting, focus on HbA1C levels can lead to serious harms for patients, especially as more diabetes drugs are needed to keep HbA1C within desired targets.

Wide geographic differences exist in treating diabetes

July 29, 2016

A large-scale observational study led by Columbia University researchers may offer new approach to studying diverse patient groups.

Patient navigators can benefit diabetes outcomes

June 29, 2016

Study seeks to determine whether significant improvement in glycemic control can be achieved when regular coaching is part of the process.

Pharma company keeps pace with rise of diabetes

May 31, 2016

Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.

3 ways to improve diabetes med adherence

May 31, 2016

A systemic review highlights studies that improved medication adherence and patient outcomes using strategies that could be effective if employed in real-world healthcare settings.

ADA: Canola oil can help control blood glucose in people with type 2 diabetes

June 17, 2014

Unhydrogenated, unsaturated vegetable oils, such as canola oil, can have health advantages when included in as part of a low-glycemic index (GI) diet in people with type 2 diabetes, according to research presented at American Diabetes Association Scientific Sessions in San Francisco, and published in Diabetes Care.

Hypoglycemic event in elderly raises dementia risk

June 10, 2013

Older adults with diabetes mellitus may be at increased risk for Alzheimer’s disease or vascular dementia following a hypoglycemic event, according to a study published online by JAMA Internal Medicine on June 10th.

Congressional coalition rallies against CMS ban on pharmacy home deliveries of diabetes testing supplies

June 04, 2013

Forty-three members of Congress are urging the Centers for Medicare and Medicaid Services (CMS) not to implement a new policy that prohibits independent community pharmacies from providing same-day, home delivery of diabetes testing supplies (DTS) to homebound seniors.

Standards of medical care in diabetes: focus on updated recommendations in hospitalized patients

June 01, 2013

Although the prevalence of diabetes mellitus in hospitalized patients remains unknown, an estimated one-fourth of inpatients experience hyperglycemia.1 Hyperglycemia is linked to poor health outcomes, and there is evidence that intensive glucose control in the hospital reduces mortality, need for dialysis, infections, and length of stay.2 The American Diabetes Association (ADA) publishes clinical practice guidelines annually, which offer clinicians, patients, researchers, and payers current, evidence-based recommendations on all components of diabetes care, general treatment goals, and tools to evaluate the quality of care. The updated guidelines focus on changes in the recommendations for care of the hospitalized diabetes patient.

New molecular entity: Canagliflozin

June 01, 2013

On March 29, 2013, FDA approved canagliflozin (Invokana, Janssen Pharmaceuticals, Inc.), a once-daily tablet, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

New biologic Xeljanz Tofacitinib Pfizer

May 01, 2013

In November 2012, FDA approved tofacitinib (Xeljanz, Pfizer) 5 mg tablets for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have not had an adequate response to methotrexate or are intolerant to methotrexate. Tofacitinib, an oral non-biologic disease-modifying antirheumatic drug (DMARD) can be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. It is contraindicated for use with biologic DMARDs or with immunosuppressive agents, such as azathioprine and cyclosporine.

Canagliflozin approval ushers in new approach to T2DM

April 02, 2013

FDA’s recent approval of canagliflozin (Invokana, Janssen Pharmaceuticals) for adults with type 2 diabetes (T2DM), represents a new efficacy and unique approach to diabetes treatment, according to industry experts.